PDF(1556 KB)
Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: a Meta analysis
WEI Yan, LI Dong-Sheng, LIU Jian-Jun, ZHANG Jing, ZHAO Hai-En
Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (11) : 1100-1105.
PDF(1556 KB)
PDF(1556 KB)
Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: a Meta analysis
Objective To evaluate the therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma. Methods The databases CNKI, Wanfang Data, VIP, PubMed, EMbase, and BioMed Central were searched for randomized controlled trials (RCTs) of montelukast sodium combined with budesonide in the treatment of children with cough variant asthma. Data extraction and quality assessment were performed for RCTs which met the inclusion criteria, and RevMan 5.3 software was used to perform quality assessment of the articles included and Meta analysis. Results A total of 11 RCTs involving 1 097 patients were included. The results of the Meta analysis showed that compared with the control group (inhalation of budesonide alone), the observation group (inhalation of montelukast sodium combined with budesonide) had significantly higher overall response rate and more improved pulmonary function parameters including forced expiratory volume in the first second, percentage of forced expiratory volume in the first second, and peak expiratory flow, as well as significantly lower recurrence rate (P < 0.01). The incidence of adverse events showed no significant difference between the two groups. Conclusions Inhalation of montelukast sodium combined with budesonide has a significant effect in children with cough variant asthma and does not increase the incidence of adverse events.
Montelukast sodium / Budesonide / Cough variant asthma / Meta analysis / Child
[1] 中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南(2009版)(一)[J].全科医学临床与教育,2009,7(5):453-456.
[2] 中国儿童慢性咳嗽病因构成比研究协作组.中国儿童慢性咳嗽病因构成比多中心研究[J].中华儿科杂志,2012,50(2):83-92.
[3] Todokoro M,Mochizuki H,Tokuyama K,et al.Childhood cough variant asthma and its relationship to classic asthma[J].Ann Allergy Asthma Immunol,2003,90(6):652-659.
[4] 中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南[J].中华儿科杂志,2008,46(10):745-753.
[5] 全国儿科哮喘防治协作组.儿童哮喘防治常规(试行)[J].中华儿科杂志,1998,36(12):747-751.
[6] Higgins JPT,Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[EB/OL].(March 2011).http://handbook.cochrane.org.
[7] 丁妮娜,王航娜.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效观察[J].中国伤残医学,2014,22(18):154-155.
[8] 丁涛,张士辉.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的临床疗效和安全性评价[J].医学综述,2015,21(14):2637-2638.
[9] 万小华,周治球,徐淑娟,等.孟鲁司特钠联合布地奈德对小儿咳嗽变异性哮喘的临床分析[J].当代医学,2015,21(29):144-145.
[10] 侯蓉.孟鲁司特在小儿咳嗽变异性哮喘治疗中的疗效观察[J].西南国防医药,2012,22(6):619-621.
[11] 尹秀芹.孟鲁司特联合布地奈德治疗小儿咳嗽变异性哮喘的疗效分析[J].中国现代医生,2015,53(9):73-75.
[12] 李玲,苟洪波,文亚娜,等.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效研究[J].重庆医学,2013,42(34):4198-4199.
[13] 谢毅,陈静.孟鲁司特联合布地奈德在小儿咳嗽变异性哮喘中的疗效分析[J].国际病理科学与临床杂志,2012,32(2):114-117.
[14] 辛长顺,周长慧.布地奈德混悬液联合孟鲁斯特钠治疗小儿咳嗽变异性哮喘的临床观察[J].中国实用医药,2013,8(8):149-151.
[15] 陈海燕.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效[J].中国药物经济学,2014,9(9):62-63.
[16] 陈群燕.孟鲁司特钠联合布地奈德雾化吸入治疗儿童咳嗽变异性哮喘的临床观察[J].临床合理用药杂志,2014,7(6C):7-8.
[17] 马红梅,刘香莲.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的作用分析[J].海南医学院学报,2015,21(3):350-352.
[18] 胡红.咳嗽变异性哮喘的诊断及治疗进展[J].解放军医学杂志,2014,39(5):361-364.
[19] 方芬,谭毅.咳嗽变异性哮喘与白三烯关系的研究进展[J].中国临床新医学,2013,6(1):87-90.
[20] Global Initiative for Asthma (GINA).Global Strategy for Asthma Management and Prevention (2014 revision)[EB/OL].[Novermber 23,2015].http://www.ginasthma.org.
[21] 中华医学会儿科学分会呼吸学组慢性咳嗽协作组,《中华儿科杂志》编辑委员会.中国儿童慢性咳嗽诊断与治疗指南(2013年修订)[J].中华儿科杂志,2014,52(3):184-188.
[22] Majak P,Rychlik B,Pulaski L,et al.Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma[J].J Allergy Clin Immunol,2010,125(6):1220-1227.
